Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06373458 · ClinicalTrials.gov registry record · Phase 2
Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy
A Phase 2 study of Keloid, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06373458: Recruiting Phase 2 study of Keloid, sponsored by Icahn School of Medicine at Mount Sinai.
NCT06373458 is a Phase 2 study of Keloid that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 30 participants, below the 2,141-participant average among 8 other Keloid trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06373458, a Phase 2 study of Keloid, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Keloids are common, benign cutaneous overgrowths that manifest clinically as raised, hypertrophic, often hyperpigmented lesions which are formed in response to dermal injury or idiopathic stimuli. Although keloids are a common disease, it's exact incidence and prevalence is not known. Despite the debilitating nature of keloids, current treatment modalities are limited in efficacy; there is no universally effective therapy available to patients. The research team hypothesize that ritlecitinib as a JAK3/TEC inhibitor will be able to reverse both the systemic and local keloid disease process by re-establishing immune homeostasis.
Primary Outcome
Recurrence Rate at 9 months (Visit 9) in subjects that received keloidectomy
Conditions Studied
Interventions
- DRUG Ritlecitinib
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-08-13 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
What NCT06373458 shows while recruiting
NCT06373458 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,141-participant average among 8 other Keloid trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Keloid appearing as the primary indexed condition, and to 1 intervention - of which Ritlecitinib is the first listed.
NCT06373458 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06373458 about?
NCT06373458 is a clinical study titled "Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy". Keloids are common, benign cutaneous overgrowths that manifest clinically as raised, hypertrophic, often hyperpigmented lesions which are formed in response to dermal injury or idiopathic stimuli. Although keloids are a common disease, it's exact incidence and prevalence is not known. Despite the de...
What is the current status of trial NCT06373458?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-08-13. Estimated completion is 2027-08.
What conditions does trial NCT06373458 study?
This clinical trial studies the following conditions: Keloid.
What interventions are being tested in trial NCT06373458?
The interventions under investigation include: Ritlecitinib (DRUG).
Who is sponsoring clinical trial NCT06373458?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06373458 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keloid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06373458's enrollment target sits among peer trials
30 4th of 8 higher than 5 of 8 other Keloid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Keloid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Radiotherapy for Keloids
RECRUITING · NA
-
Genetic Analysis of Keloids
RECRUITING
-
Web Based Investigation of Natural History of Keloid Disorder, an Online Survey
RECRUITING
-
RAPA-Keloid Study of Keloid Regression
COMPLETED · Early Phase 1
-
Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids
COMPLETED · Early Phase 1
-
Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI